TORONTO, Feb. 19 /CNW/ - Defyrus Inc. today announced the signing an
exclusive, worldwide license to a patent portfolio created by the United
Kingdom's Defence Science and Technology Laboratory (Dstl) and licensed by
Ploughshare Innovation Ltd, Dstl's commercialization company. These patents
form the intellectual property foundation of the Company's vaccine product
development programs. Defyrus and Ploughshare Innovation Ltd plan to expand
their commercial interaction in 2009 to include preclinical safety and
efficacy studies as part of the Company's vaccine development program. The
commercial terms of the license were not disclosed.
The licensed technology of 27 issued & pending international patents,
describes the production of multi-valent vaccines for the treatment of
alpha-viral infections resulting from bioterrorism or endemic disease. These
highly infectious, mosquito-borne encephalitis viruses pose a serious risk to
people and livestock for which no vaccine or therapy exists.
"Dstl has pioneered the investigation of effective medical
countermeasures (e.g. vaccines and drugs) for the treatment of a number of
important biological diseases that are potential biological warfare threats.
Their unique approach to vaccine development and compelling animal efficacy
data for viral encephalitis made this license attractive" commented Dr.
Jeffrey D. Turner, President & CEO of Defyrus, "We see tremendous synergy in
levering investor capital with successful Government R&D programs to drive
cost-effective, rapid drug development forward. Improving our capability to
respond to viral threats from endemic disease or biological warfare is our
mission and represents a significant contribution to protecting the
international community from dangerous pathogens".
"Defyrus' business model has the hallmark of a true public-private
collaboration. In licensing Dstl's technology to Defyrus, whose management
team have a proven track record in vaccine development, Ploughshare expects
that Dstl's pioneering work can be rapidly translated into vaccines that are
available for both the public health markets in the developing world, as well
as the North American and European defence markets" stated Andy Tulloch, Chief
Executive Officer Ploughshare Innovations. "We look forward to expanding our
interactions with Defyrus in the years to come" added Dr. David Harris, Head
of Technology Transfer at Dstl.
Defyrus is a private, life sciences biodefence company that collaborates
with domestic and international military R&D partners to develop a range of
therapeutics as medical countermeasures for civilians and military personnel.
About Ploughshare Innovations & Dstl
Ploughshare is wholly owned by the United Kingdom's Secretary of State
for Defence and facilitates the commercialization of defence technologies
arising from Dstl. Dstl is an agency of the UK's Ministry of Defence (MoD),
existing to supply the very best, impartial, scientific and technical research
and advice to the MoD and other Government Departments. Dstl houses one of the
largest groups of scientists and engineers (3,500-strong work force) in public
service in the UK and supports procurement decisions, defence policy-making
and operations. www.ploughshareinnovations.com & www.dstl.gov.uk
For further information:
For further information: Dr. Jeffrey D. Turner, President & CEO, Defyrus
Inc, Tel: (613) 674-1138, email@example.com; Dr. Taj S. Mattu, Marketing
Manager, Ploughshare Innovations, Tel: +44 (0) 1980 690062,